Evidence map›Paper›PMID 33388232›Full record

ArticleJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy2021

Evaluation of clinical utility of novel coronavirus antigen detection reagent, Espline® SARS-CoV-2.

Kotaro Aoki, Tatsuya Nagasawa, Yoshikazu Ishii, Shintaro Yagi, Katsuhito Kashiwagi, Taito Miyazaki, Kazuhiro Tateda

Abstract read
In one paragraph

Article in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing (January 2023).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Guideline
  2. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.The Cochrane database of systematic reviews · 2022
    Pooled it
  3. Pooled it
  4. Evaluation of an immunochromatography-based rapid antigen test, Inspecter Kowa® SARS-CoV-2, using saliva specimens for the detection of SARS-CoV-2.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2023
    Article
  5. Article
  6. Analysis of diagnostic performance and factors causing nonspecific reactions in SARS-CoV-2 rapid antigen detection tests.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2023
    Article
  7. Review
  8. ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kotaro AokiDepartment of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, 143-8540, Tokyo, Japan.
Tatsuya NagasawaDepartment of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, 143-8540, Tokyo, Japan.
Yoshikazu IshiiDepartment of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, 143-8540, Tokyo, Japan. Electronic address: yishii@med.toho-u.ac.jp.
Shintaro YagiFujirebio Inc., 51 Komiya-machi, Hachioji, 192-0031, Tokyo, Japan.
Katsuhito KashiwagiGeneral Medicine and Emergency Center (Internal Medicine), Toho University Omori Medical Center, 6-11-1 Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan.
Taito MiyazakiGeneral Medicine and Emergency Center (Internal Medicine), Toho University Omori Medical Center, 6-11-1 Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan.
Kazuhiro TatedaDepartment of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, 143-8540, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo prevent the novel coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is necessary to perform early identification and isolation of people shedding the infectious virus in biological materials with high viral loads several days prior to symptom onset. Rapid antigen tests for infectious diseases are useful to prevent the pandemic spread in clinical settings.

methodsWe evaluated a SARS-CoV-2 antigen test, Espline® SARS-CoV-2 reagent, with reverse transcription polymerase chain reaction (RT-PCR) as reference test, using 129 nasopharyngeal swab specimens collected from COVID-19 hospitalized patients or from patients suspected having COVID-19-like symptoms. Out of these, 63 RT-PCR positive and 66 RT-PCR negative specimens were identified.

resultsAmong 63 RT-PCR positive specimens, 25 were positive in the Espline test. Test sensitivity was estimated based on the 532.4 copies/reaction of SARS-CoV-2 RNA obtained through receiver operating characteristic analysis. When the specimens were classified based on time since symptom onset, Espline test sensitivity were 73.3% and 29.2% in specimens collected before day 9 and after day 10, respectively.

conclusionAlthough the overall sensitivity of the Espline® SARS-CoV-2 reagent compared with RT-PCR is less, this antigen test can be useful in identifying people with high risk of virus transmission with high viral loads in order to prevent the pandemic and is useful for diagnosing COVID-19 within 30 min.

Indexed as

Antigens, ViralCOVID-19COVID-19 Serological TestingHumansIndicators and ReagentsNasopharynxPandemicsReverse Transcriptase Polymerase Chain ReactionRNA, ViralROC CurveSARS-CoV-2Sensitivity and SpecificityViral LoadAntigens, ViralIndicators and ReagentsRNA, ViralAntigen detectionCOVID-19DiagnosisImmunochromatographySARS-CoV-2

Identifiers

PMID33388232
PMCPMC7757343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.